Biowaiver for one strength/dose of non-linear PK [Design Issues]

posted by Tina – India, 2016-05-26 15:58 (3328 d 18:10 ago) – Posting: # 16363
Views: 2,627

Dear all,
Iam currently working on a BE study (with an anticancer drug) in cancer patients for EU submission. A higher dose is linear whilst the lower dose (in a different group of cancer patients) is non-linear. BE study with a higher dose can be planned. However, being rare condition, lower dose/strength cant be planned. Could the group members kindly help with providing a solution to waive BE study with the lower dose/strength (with non-linear pk) please? The irony is some patients in the main indication could also receive the lower dose/strength…recruitment of such patients will still be an issue. Has anyone received biowaiver for non-linear PK drug by conduct of a single study and justifying the non-conduct of the other?
Thank you for the kind help.
Kind regards,
Tina


Edit: Category changed; see also this post #1. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,427 posts in 4,929 threads, 1,681 registered users;
65 visitors (0 registered, 65 guests [including 17 identified bots]).
Forum time: 10:09 CEST (Europe/Vienna)

No matter what side of the argument you are on,
you always find people on your side
that you wish were on the other.    Thomas Berger

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5